太极拳锻炼对衰老影响-队列研究

注册号:

Registration number:

ChiCTR1900025189 

最近更新日期:

Date of Last Refreshed on:

2019-08-15 23:25:38 

注册时间:

Date of Registration:

2019-08-15 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

太极拳锻炼对衰老影响-队列研究

Public title:

Anti-ageing effects of Tai Chi: a cohort study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

太极拳锻炼对衰老影响-队列研究

Scientific title:

Anti-ageing effects of Tai Chi: a cohort study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李丽莉 

研究负责人:

王志华 

Applicant:

Lili Li 

Study leader:

Zhihua Wang 

申请注册联系人电话:

Applicant telephone:

+86 13307107535

研究负责人电话:

Study leader's
telephone:

+86 18163306735

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

26061047@qq.com

研究负责人电子邮件:

Study leader's E-mail:

zhihuawang@whu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

武汉大学人民医院张之洞路95号临床第一学院中心实验室

研究负责人通讯地址:

武汉大学人民医院张之洞路95号临床第一学院中心实验室

Applicant address:

95 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China

Study leader's address:

95 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China

申请注册联系人邮政编码:

Applicant postcode:

430060

研究负责人邮政编码:

Study leader's postcode:

430060

申请人所在单位:

武汉大学人民医院

Applicant's institution:

Renmin Hospital of Wuhan University

研究负责人所在单位:

武汉大学人民医院

Affiliation of the Leader:

Renmin Hospital of Wuhan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017K-C046

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

武汉大学人民医院临床研究伦理委员会

Name of the ethic committee:

Clinical Research Ethics Committee,Renmin Hospital of Wuhan University

伦理委员会批准日期:

Date of approved by ethic committee:

2017-12-11 00:00:00

伦理委员会联系人:

黄珍

Contact Name of the ethic committee:

Zhen Huang

伦理委员会联系地址:

武汉市武昌区张之洞路99号武汉大学人民医院学术活动中心609

Contact Address of the ethic committee:

Renmin Hospital of Wuhan University, 95 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

武汉大学人民医院

Primary sponsor:

Renmin Hospital of Wuhan University

研究实施负责(组长)单位地址:

武汉市武昌区张之洞路99号

Primary sponsor's address:

95 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北省

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

武汉大学人民医院

具体地址:

武汉市武昌区张之洞路99号

Institution
hospital:

Renmin Hospital of Wuhan University

Address:

95 Zhangzhidong Road, Wuchang District, Wuhan, Hubei, China

国家:

中国

省(直辖市):

湖北省

市(区县):

Country:

China

Province:

Hubei

City:

单位(医院):

武汉体育学院

具体地址:

武汉市洪山区珞瑜路461号

Institution
hospital:

Wuhan Institute of Physical Education

Address:

461 Luoyu Road, Hongshan District, Wuhan

经费或物资来源:

自筹

Source(s) of funding:

self-finaced programs

研究疾病:

衰老  

Target disease:

Ageing

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

随着我国逐渐步入老龄社会,老龄相关问题空前凸显。衰老是一个器官功能退化的过程,衰老相关疾病涉及了心血管病、肿瘤、神经退行性疾病、代谢性疾病等各大领域。太极拳是一项适宜老年人的柔和的运动方式,其抗衰老作用已被多项研究证实,但目前还没有研究对其抗衰老的机理从分子水平进行揭示。本课题拟通过多种组学手段,揭示太极拳抗衰老作用的分子基础,并阐明关键基因作用的分子机制,从而鉴定临床转化研究潜在的分子靶点,提出衰老相关疾病临床防治的新策略。  

Objectives of Study:

China gradually become an ageing society, issues related to ageing are unprecedented. Ageing is a process of degeneration of organ function. Many diseases related to ageing, including cardiovascular disease, tumor, neurodegenerative disease and metabolic disease. Tai Chi is a gentle exercise form suitable for the elderly. Its anti-ageing effect has been confirmed by many studies, but the mechanism of its anti-ageing has not been revealed at the molecular level. This topic intends to reveal the molecular basis of the anti-aging effect of Tai Chi through a variety of omics methods, clarify the molecular mechanism of key genes, identify potential molecular targets, and propose a new strategy for clinical prevention and treatment of ageing-related diseases.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1)2周内有严重腹泻、呕吐等症状
2)1月内有明显发热等感冒症状
3)1月内有大量饮酒史(酗酒),或长期大量饮酒史
4)2月内体重出现明显波动(变化大于5Kg)
5)半年内有手术史或严重外伤史
6)有甲亢、肝炎等病史
7)存在抑郁或精神障碍等,可疑者需做抑郁量表和精神状态量表确认

Exclusion criteria:

1) There are symptoms such as severe diarrhea and vomiting within 2 weeks;
2) There is obvious fever and other cold symptoms within one month;
3) A large history of drinking (alcoholism), or a long history of heavy drinking;
4) The body weight fluctuated significantly within 2 months (change is greater than 5Kg);
5) History of surgery or history of severe trauma within six months;
6) Have a history of hyperthyroidism, hepatitis, etc.;
7) Depression or mental disorder, suspicious persons need to confirm the depression scale and mental state scale.

研究实施时间:

Study execute time:

From 2017-12-01 00:00:00 To 2019-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-12-12 00:00:00 To 2019-12-31 00:00:00

干预措施:

Interventions:

组别:

老年组

样本量:

300

Group:

Case series

Sample size:

干预措施:

太极锻炼

干预措施代码:

Intervention:

Taiji exercise

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北省 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉大学人民医院 

单位级别:

三级甲等医院 

Institution
hospital:

Renmin Hospital of Wuhan University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

血常规

指标类型:

主要指标

Outcome:

Routine blood testing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖血脂

指标类型:

主要指标

Outcome:

Blood sugar/lipid testing

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脑血管功能

指标类型:

主要指标

Outcome:

Cerebrovascular function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心脏功能

指标类型:

主要指标

Outcome:

Cardiac function

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

骨密度

指标类型:

主要指标

Outcome:

Bone marrow density

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

胰岛素样生长因子1

指标类型:

主要指标

Outcome:

IGF-1

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生长激素

指标类型:

主要指标

Outcome:

Growth hormone

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

大便

组织:

Sample Name:

stool

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

N/A

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

N/A

Blinding:

N/A

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

实验结束后,即2020年12月份之前于数据公开,网址http://www.chictr.org.cn, https://www.ncbi.nlm.nih.gov/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data will be uploade in public database before December 2019. http://www.chictr.org.cn, https://www.ncbi.nlm.nih.gov/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

http://www.medresman.org

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

http://www.medresman.org

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2019-08-15 23:25:38